Search Results - "BLISS, Judith"

Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial by Murray Brunt, Adrian, Haviland, Joanne S, Wheatley, Duncan A, Sydenham, Mark A, Alhasso, Abdulla, Bloomfield, David J, Chan, Charlie, Churn, Mark, Cleator, Susan, Coles, Charlotte E, Goodman, Andrew, Harnett, Adrian, Hopwood, Penelope, Kirby, Anna M, Kirwan, Cliona C, Morris, Carolyn, Nabi, Zohal, Sawyer, Elinor, Somaiah, Navita, Stones, Liba, Syndikus, Isabel, Bliss, Judith M, Yarnold, John R, Alhasso, Abdulla, Armstrong, Anne, Bliss, Judith, Bloomfield, David, Bowen, Jo, Brunt, Murray, Chan, Charlie, Chantler, Hannah, Churn, Mark, Cleator, Susan, Coles, Charlotte, Donovan, Ellen, Goodman, Andy, Griffin, Susan, Haviland, Jo, Hopwood, Penny, Kirby, Anna, Kirk, Julie, Kirwan, Cliona, MacLennan, Marjory, Morris, Carolyn, Nabi, Zohal, Sawyer, Elinor, Sculphur, Mark, Sinclair, Judith, Somaiah, Navita, Stones, Liba, Sydenham, Mark, Syndikus, Isabel, Tremlett, Jean, Venables, Karen, Wheatley, Duncan, Yarnold, John

“…We aimed to identify a five-fraction schedule of adjuvant radiotherapy (radiation therapy) delivered in 1 week that is non-inferior in terms of local cancer…”
Get full text

Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer by O’Leary, Ben, Hrebien, Sarah, Morden, James P., Beaney, Matthew, Fribbens, Charlotte, Huang, Xin, Liu, Yuan, Bartlett, Cynthia Huang, Koehler, Maria, Cristofanilli, Massimo, Garcia-Murillas, Isaac, Bliss, Judith M., Turner, Nicholas C.

“…CDK4/6 inhibition substantially improves progression-free survival (PFS) for women with advanced estrogen receptor-positive breast cancer, although there are…”
Get full text

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer by Fribbens, Charlotte, O'Leary, Ben, Kilburn, Lucy, Hrebien, Sarah, Garcia-Murillas, Isaac, Beaney, Matthew, Cristofanilli, Massimo, Andre, Fabrice, Loi, Sherene, Loibl, Sibylle, Jiang, John, Bartlett, Cynthia Huang, Koehler, Maria, Dowsett, Mitch, Bliss, Judith M, Johnston, Stephen R D, Turner, Nicholas C

“…ESR1 mutations are selected by prior aromatase inhibitor (AI) therapy in advanced breast cancer. We assessed the impact of ESR1 mutations on sensitivity to…”
Get full text

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer by Chopra, Neha, Tovey, Holly, Pearson, Alex, Cutts, Ros, Toms, Christy, Proszek, Paula, Hubank, Michael, Dowsett, Mitch, Dodson, Andrew, Daley, Frances, Kriplani, Divya, Gevensleben, Heidi, Davies, Helen Ruth, Degasperi, Andrea, Roylance, Rebecca, Chan, Stephen, Tutt, Andrew, Skene, Anthony, Evans, Abigail, Bliss, Judith M., Nik-Zainal, Serena, Turner, Nicholas C.

“…Triple negative breast cancer (TNBC) encompasses molecularly different subgroups, with a subgroup harboring evidence of defective homologous recombination (HR)…”
Get full text

The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials by Haviland, Joanne S, MSc, Owen, J Roger, FRCR, Dewar, John A, Prof, Agrawal, Rajiv K, FRCR, Barrett, Jane, FRCR, Barrett-Lee, Peter J, Prof, Dobbs, H Jane, FRCR, Hopwood, Penelope, MD, Lawton, Pat A, PhD, Magee, Brian J, FRCR, Mills, Judith, MPhil, Simmons, Sandra, Sydenham, Mark A, BSc, Venables, Karen, PhD, Bliss, Judith M, Prof, Yarnold, John R, Prof

“…Summary Background 5-year results of the UK Standardisation of Breast Radiotherapy (START) trials suggested that lower total doses of radiotherapy delivered in…”
Get full text

Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial by Smith, Ian, Robertson, John, Kilburn, Lucy, Wilcox, Maggie, Evans, Abigail, Holcombe, Chris, Horgan, Kieran, Kirwan, Cliona, Mallon, Elizabeth, Sibbering, Mark, Skene, Anthony, Vidya, Raghavan, Cheang, Maggie, Banerji, Jane, Morden, James, Sidhu, Kally, Dodson, Andrew, Bliss, Judith M, Dowsett, Mitch

“…Preoperative and perioperative aromatase inhibitor (POAI) therapy has the potential to improve outcomes in women with operable oestrogen receptor-positive…”
Get full text

Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer by Brunt, Adrian Murray, Haviland, Joanne S, Sydenham, Mark, Agrawal, Rajiv K, Algurafi, Hafiz, Alhasso, Abdulla, Barrett-Lee, Peter, Bliss, Peter, Bloomfield, David, Bowen, Joanna, Donovan, Ellen, Goodman, Andy, Harnett, Adrian, Hogg, Martin, Kumar, Sri, Passant, Helen, Quigley, Mary, Sherwin, Liz, Stewart, Alan, Syndikus, Isabel, Tremlett, Jean, Tsang, Yat, Venables, Karen, Wheatley, Duncan, Bliss, Judith M, Yarnold, John R

“…Previous studies of hypofractionated adjuvant whole-breast radiotherapy for early breast cancer established a 15- or 16-fraction (fr) regimen as standard. The…”
Get full text

Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study by Treasure, Tom, Prof, Lang-Lazdunski, Loic, MD, Waller, David, FRCS [CTh], Bliss, Judith M, Prof, Tan, Carol, FRCS [CTh], Entwisle, James, FRCR, Snee, Michael, DM, O'Brien, Mary, MD, Thomas, Gill, FRCR, Senan, Suresh, Prof, O'Byrne, Ken, Prof, Kilburn, Lucy S, MSc, Spicer, James, MRCP, Landau, David, FRCR, Edwards, John, FRCS [CTh], Coombes, Gill, RGN, Darlison, Liz, RGN, Peto, Julian, Prof

“…Summary Background The effects of extra-pleural pneumonectomy (EPP) on survival and quality of life in patients with malignant pleural mesothelioma have, to…”
Get full text

Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial by Turner, Nicholas C, Kingston, Belinda, Kilburn, Lucy S, Kernaghan, Sarah, Wardley, Andrew M, Macpherson, Iain R, Baird, Richard D, Roylance, Rebecca, Stephens, Peter, Oikonomidou, Olga, Braybrooke, Jeremy P, Tuthill, Mark, Abraham, Jacinta, Winter, Matthew C, Bye, Hannah, Hubank, Michael, Gevensleben, Heidrun, Cutts, Ros, Snowdon, Claire, Rea, Daniel, Cameron, David, Shaaban, Abeer, Randle, Katrina, Martin, Sue, Wilkinson, Katie, Moretti, Laura, Bliss, Judith M, Ring, Alistair

“…Circulating tumour DNA (ctDNA) testing might provide a current assessment of the genomic profile of advanced cancer, without the need to repeat tumour biopsy…”
Get full text

ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials by Turner, Nicholas C, Swift, Claire, Kilburn, Lucy, Fribbens, Charlotte, Beaney, Matthew, Garcia-Murillas, Isaac, Budzar, Aman U, Robertson, John F R, Gradishar, William, Piccart, Martine, Schiavon, Gaia, Bliss, Judith M, Dowsett, Mitch, Johnston, Stephen R D, Chia, Stephen K

“…mutations are acquired frequently in hormone receptor-positive metastatic breast cancer after prior aromatase inhibitors. We assessed the clinical utility of…”
Get full text

Effect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial by Goodwin, Pamela J, Chen, Bingshu E, Gelmon, Karen A, Whelan, Timothy J, Ennis, Marguerite, Lemieux, Julie, Ligibel, Jennifer A, Hershman, Dawn L, Mayer, Ingrid A, Hobday, Timothy J, Bliss, Judith M, Rastogi, Priya, Rabaglio-Poretti, Manuela, Mukherjee, Som D, Mackey, John R, Abramson, Vandana G, Oja, Conrad, Wesolowski, Robert, Thompson, Alastair M, Rea, Daniel W, Stos, Paul M, Shepherd, Lois E, Stambolic, Vuk, Parulekar, Wendy R

“…IMPORTANCE: Metformin, a biguanide commonly used to treat type 2 diabetes, has been associated with potential beneficial effects across breast cancer subtypes…”
Get full text

Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial by Coles, Charlotte E, Griffin, Clare L, Kirby, Anna M, Titley, Jenny, Agrawal, Rajiv K, Alhasso, Abdulla, Bhattacharya, Indrani S, Brunt, Adrian M, Ciurlionis, Laura, Chan, Charlie, Donovan, Ellen M, Emson, Marie A, Harnett, Adrian N, Haviland, Joanne S, Hopwood, Penelope, Jefford, Monica L, Kaggwa, Ronald, Sawyer, Elinor J, Syndikus, Isabel, Tsang, Yat M, Wheatley, Duncan A, Wilcox, Maggie, Yarnold, John R, Bliss, Judith M, Al Sarakbi, Wail, Barber, Sarah, Barnett, Gillian, Bliss, Peter, Dewar, John, Eaton, David, Ebbs, Stephen, Ellis, Ian, Evans, Philip, Harris, Emma, James, Hayley, Kirwan, Cliona, Kirk, Julie, Mayles, Helen, McIntyre, Anne, Mills, Judith, Poynter, Andrew, Provenzano, Elena, Rawlings, Christine, Sculpher, Mark, Sumo, Georges, Sydenham, Mark, Tutt, Andrew, Twyman, Nicola, Venables, Karen, Winship, Anna, Winstanley, John, Wishart, Gordon, Thompson, Alastair

“…Local cancer relapse risk after breast conservation surgery followed by radiotherapy has fallen sharply in many countries, and is influenced by patient age and…”
Get full text

Dissecting the Heterogeneity of Triple-Negative Breast Cancer by METZGER-FILHO, Otto, TUTT, Andrew, DI LEO, Angelo, BASELGA, José, SOTIRIOU, Christos, PICCART-GEBHART, Martine, DE AZAMBUJA, Evandro, SAINI, Kamal S, VIALE, Giuseppe, LOI, Sherene, BRADBURY, Ian, BLISS, Judith M, AZIM, Hatem A, ELLIS, Paul

“…Triple-negative breast cancer (TNBC) accounts for 15% to 20% of breast cancers. It is a heterogeneous disease, not only on the molecular level, but also on the…”
Get full text

Implementation of platform trials in the COVID-19 pandemic: A rapid review by Vanderbeek, Alyssa M., Bliss, Judith M., Yin, Zhulin, Yap, Christina

“…Platform designs - master protocols that allow for new treatment arms to be added over time - have gained considerable attention in recent years. Between 2001…”
Get full text

Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial by Hayes, Andrew J, Dr, Maynard, Lauren, MSc, Coombes, Gillian, RN, Newton-Bishop, Julia, Prof, Timmons, Michael, FRCS, Cook, Martin, Prof, Theaker, Jeffrey, FRCPath, Bliss, Judith M, Prof, Thomas, J Meirion, FRCS

“…Summary Background The necessary margin of excision for cutaneous melanomas greater than 2 mm in thickness is controversial. At a median follow-up of 5 years,…”
Get full text

Late normal tissue effects in the arm and shoulder following lymphatic radiotherapy: Results from the UK START (Standardisation of Breast Radiotherapy) trials by Haviland, Joanne S, Mannino, Mariella, Griffin, Clare, Porta, Nuria, Sydenham, Mark, Bliss, Judith M., Yarnold, John R.

“…Adjuvant lymphatic radiotherapy (LNRT) is recommended for selected axillary node positive women with early breast cancer. We investigated whether…”
Get full text

Genomic profile of advanced breast cancer in circulating tumour DNA by Kingston, Belinda, Cutts, Rosalind J., Bye, Hannah, Beaney, Matthew, Walsh-Crestani, Giselle, Hrebien, Sarah, Swift, Claire, Kilburn, Lucy S., Kernaghan, Sarah, Moretti, Laura, Wilkinson, Katie, Wardley, Andrew M., Macpherson, Iain R., Baird, Richard D., Roylance, Rebecca, Reis-Filho, Jorge S., Hubank, Michael, Faull, Iris, Banks, Kimberly C., Lanman, Richard B., Garcia-Murillas, Isaac, Bliss, Judith M., Ring, Alistair, Turner, Nicholas C.

“…The genomics of advanced breast cancer (ABC) has been described through tumour tissue biopsy sequencing, although these approaches are limited by geographical…”
Get full text

Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial by Brunt, A. Murray, Wheatley, Duncan, Yarnold, John, Somaiah, Navita, Kelly, Stephen, Harnett, Adrian, Coles, Charlotte, Goodman, Andrew, Bahl, Amit, Churn, Mark, Zotova, Rada, Sydenham, Mark, Griffin, Clare L, Morden, James P, Bliss, Judith M

“…Abstract Background and purpose FAST-Forward is a phase 3 clinical trial testing a 1-week course of whole breast radiotherapy against the UK standard 3-week…”
Get full text

Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03) by Gnant, Michael, Dueck, Amylou C, Frantal, Sophie, Martin, Miguel, Burstein, Hal J, Greil, Richard, Fox, Peter, Wolff, Antonio C, Chan, Arlene, Winer, Eric P, Pfeiler, Georg, Miller, Kathy D, Colleoni, Marco, Suga, Jennifer M, Rubovsky, Gabor, Bliss, Judith M, Mayer, Ingrid A, Singer, Christian F, Nowecki, Zbigniew, Hahn, Olwen, Thomson, Jacqui, Wolmark, Norman, Amillano, Kepa, Rugo, Hope S, Steger, Guenther G, Hernando Fernández de Aránguiz, Blanca, Haddad, Tufia C, Perelló, Antonia, Bellet, Meritxell, Fohler, Hannes, Metzger Filho, Otto, Jallitsch-Halper, Anita, Solomon, Kadine, Schurmans, Céline, Theall, Kathy P, Lu, Dongrui R, Tenner, Kathleen, Fesl, Christian, DeMichele, Angela, Mayer, Erica L

“…Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor approved for advanced breast cancer. In the adjuvant setting, the potential value of adding…”
Get full text

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial by Johnston, Stephen RD, Prof, Kilburn, Lucy S, MSc, Ellis, Paul, Prof, Dodwell, David, Prof, Cameron, David, Prof, Hayward, Larry, MD, Im, Young-Hyuck, MD, Braybrooke, Jeremy P, MD, Brunt, A Murray, MD, Cheung, Kwok-Leung, MD, Jyothirmayi, Rema, MD, Robinson, Anne, MD, Wardley, Andrew M, MD, Wheatley, Duncan, MD, Howell, Anthony, Prof, Coombes, Gill, RGN, Sergenson, Nicole, BSc, Sin, Hui-Jung, BSc, Folkerd, Elizabeth, PhD, Dowsett, Mitch, Prof, Bliss, Judith M, Prof

“…Summary Background The optimum endocrine treatment for postmenopausal women with advanced hormone-receptor-positive breast cancer that has progressed on…”
Get full text